Ignite Creation Date:
2025-12-24 @ 11:15 PM
Ignite Modification Date:
2026-01-22 @ 7:17 AM
Study NCT ID:
NCT03580356
Status:
COMPLETED
Last Update Posted:
2025-01-07
First Post:
2018-06-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Spontaneous Urticaria | View |